毛蕊花糖苷, TRPV3 通道阻断剂

PKC抑制剂。NF-κB抑制剂。

5篇引用文献

COA

级别和纯度:

Moligand™

10mM in DMSO

CAS编号: 61276-17-3
分子式: C₂₉H₃₆O₁₅
分子量: 624.59
PubChem编号: 5281800

有货

库存信息

关闭

货号 (SKU)	包装规格	是否现货	价格	数量
V425072-1ml	1ml	现货

查看相关系列

Apoptosis (7108) Bacterial (5911) Compound libraries (12333) Histone Modification (3105) Virus (3767)

Skip to the end of the images gallery

Skip to the beginning of the images gallery

基本描述

别名	麦角甾苷
英文别名	Acteoside; Verbascoside \| VERBASCOSIDE [INCI] \| AKOS015897165 \| Q-100706 \| TJC 160 \| 2-(3,4-dihydroxyphenyl)ethyl 3-O-(6-deoxy-alpha-L-mannopyranosyl)-4-O-((2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl)-beta-D-glucopyranoside \| CCG-270269 \| cid_24978601 \| Verbascoside, United
规格或纯度	Moligand™, 10mM in DMSO
英文名称	Verbascoside
生化机理	PKC抑制剂。NF-κB抑制剂。增加PARP-1和p53。诱导细胞周期停滞和分化。抑制MMP（IC 50 = 32μM）。在体内显示出抗炎，抗伤害和抗氧化作用。口服具有活性。
储存温度	-80℃储存
运输条件	超低温冰袋运输
作用类型	通道阻滞剂
作用机制	TRPV3 通道阻断剂
产品介绍	苯乙醇糖苷。抗氧化和抗增殖。 Antioxidant and antiproliferative. Phenylethanoid glycoside.

关联靶点（人）

TRPV3 Tchem 瞬时受体电位阳离子通道亚家族V成员3(Transient receptor potential cation channel subfamily V member 3) (0 活性数据)

点击查看靶蛋白信息： TRPV3

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

名称和识别符

IIUPAC Name	[(2R,3R,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-2-(hydroxymethyl)-4-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
INCHI	1S/C29H36O15/c1-13-22(36)23(37)24(38)29(41-13)44-27-25(39)28(40-9-8-15-3-6-17(32)19(34)11-15)42-20(12-30)26(27)43-21(35)7-4-14-2-5-16(31)18(33)10-14/h2-7,10-11,13,20,22-34,36-39H,8-9,12H2,1H3/b7-4+/t13-,20+,22-,23+,24+,25+,26+,27+,28+,29-/m0/s1
InChi Key	FBSKJMQYURKNSU-ZLSOWSIRSA-N
Smiles	CC1C(C(C(C(O1)OC2C(C(OC(C2OC(=O)C=CC3=CC(=C(C=C3)O)O)CO)OCCC4=CC(=C(C=C4)O)O)O)O)O)O
Isomeric SMILES	C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H](O[C@@H]([C@H]2OC(=O)/C=C/C3=CC(=C(C=C3)O)O)CO)OCCC4=CC(=C(C=C4)O)O)O)O)O)O
PubChem CID	5281800
分子量	624.59

化学和物理性质

敏感性	吸湿、对热敏感
比旋光度	-92° (C=0.1,MeOH)
分子量	624.600 g/mol
XLogP3	-0.500
氢键供体数Hydrogen Bond Donor Count	9
氢键受体数Hydrogen Bond Acceptor Count	15
可旋转键计数Rotatable Bond Count	11
精确质量Exact Mass	624.205 Da
单同位素质量Monoisotopic Mass	624.205 Da
拓扑极表面积Topological Polar Surface Area	245.000 Å²
重原子数Heavy Atom Count	44
形式电荷Formal Charge	0
复杂度Complexity	936.000
同位素原子数Isotope Atom Count	0
定义的原子立体中心计数Defined Atom Stereocenter Count	10
未定义的原子立体中心计数Undefined Atom Stereocenter Count	0
定义的键立体中心计数Defined Bond Stereocenter Count	1
未定义的键立体中心计数Undefined Bond Stereocenter Count	0
所有立体化学键的总数The total count of all stereochemical bonds	1
共价键合单元计数Covalently-Bonded Unit Count	1

安全和危险性（GHS）

WGK Germany	2
RTECS	LZ5786000

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

此产品的引用文献

如何在您的发表作品中引用阿拉丁的产品和网站? 引用文献检索

引用文献

1. Fei Zhou, Weisu Huang, Tao Xu, Lipeng Wu, Qi Chen, Jiyu Peng, Xin Liu, Baiyi Lu. (2020) Natural P-gp inhibitor EGCG improves the acteoside absorption in Caco-2 cell monolayers and increases the oral bioavailability of acteoside in rats. FOOD AND CHEMICAL TOXICOLOGY, 146 (111827). [PMID:33184029] [10.1016/j.fct.2020.111827]
2. Si-qi Wang, Xiao Yang, Yong-gang Zhang, En-bo Cai, Xiao-man Zheng, Yan Zhao, Ge Li, Mei Han, Li-min Yang. (2020) Study on the Changes of Chemical Constituents in Different Compatibilities of Ginseng-Prepared Rehmannia Root and Their Effects on Bone Marrow Inhibition after Chemotherapy. CHEMICAL & PHARMACEUTICAL BULLETIN, 68 (5): (428-435). [PMID:32188797] [10.1248/cpb.c19-00994]
3. Fei Zhou, Tao Xu, Yajing Zhao, Huaxin Song, Liuquan Zhang, Xiaodan Wu, Baiyi Lu. (2018) Chitosan-coated liposomes as delivery systems for improving the stability and oral bioavailability of acteoside. FOOD HYDROCOLLOIDS, 83 (17). [10.1016/j.foodhyd.2018.04.040]
4. Zhou Fei, Zhao Yajing, Li Maiquan, Xu Tao, Zhang Liuquan, Lu Baiyi, Wu Xiaodan, Ge Zhiwei. (2017) Degradation of phenylethanoid glycosides in Osmanthus fragrans Lour. flowers and its effect on anti-hypoxia activity. Scientific Reports, 7 (1): (1-10). [PMID:28855701] [10.1038/s41598-017-10411-0]
5. Yong Jiang, Wenjun Ji, Ying Lu, Qin Wang, Linwei Chen. (2025) Integrating Plasma Metabolomics, Network Pharmacology, and Experimental Validation to Investigate the Action Mechanism of Qiangxin Lishui Prescription in Chronic Heart Failure. BIOMEDICAL CHROMATOGRAPHY, 39 (2): (e6065). [PMID:39748248] [10.1002/bmc.6065]